InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

After dexamethasone set a new bar for mortality reduction in COVID-19 patients this week, InflaRx and Kiniksa reported data from their anti-inflammatory mAbs showing trends toward a survival benefit.

InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday interim data showing a trend toward lower mortality in severe COVID-19 pneumonia patients treated with IFX-1 plus best supportive care vs. best supportive care alone in the Phase II portion of an adaptive Phase II/III trial. However, the company lost $1.81 (25%) to $5.39 on the readout, which showed no difference in oxygenation, the primary endpoint, between the two cohorts...